Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02792699 · ClinicalTrials.gov registry record · Phase 3
Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 311
- Enrollment target
NCT02792699 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 311 participants.
The verdict
NCT02792699, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 311 participants
- Enrollment target
Study Summary
This trial is designed to determine what effects the human body has on the investigational medicine, ABP 798, and what effects the body has on the investigational medicine after you have been given it, and if this is comparable to what is seen for the licensed medicine, rituximab, in patients with moderate or severe RA. This study will also assess if the investigational medicine is safe and effective in treating moderate or severe RA compared to the licensed medicine.
Interventions
- DRUG ABP 798
- DRUG Rituximab (US)
- DRUG Rituximab (EU)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 311 participants |
| Start Date | 2016-05-17 |
| Est. Completion | 2018-10-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02792699
The ClinicalTrials.gov registry entry for NCT02792699 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 311 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ABP 798 is the first listed.
NCT02792699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02792699 about?
NCT02792699 is a clinical study titled "Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab". This trial is designed to determine what effects the human body has on the investigational medicine, ABP 798, and what effects the body has on the investigational medicine after you have been given it, and if this is comparable to what is seen for the licensed medicine, rituximab, in patients with m...
What is the current status of trial NCT02792699?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 311 participants. The study started on 2016-05-17. Estimated completion is 2018-10-08.
What interventions are being tested in trial NCT02792699?
The interventions under investigation include: ABP 798 (DRUG), Rituximab (US) (DRUG), Rituximab (EU) (DRUG).
Who is sponsoring clinical trial NCT02792699?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.